Wechselwirkungen · Karvezide
Karvezide 150 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 6–7
HOS-089155 · Präparat HOS-083799
6 Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage 51310a74f30b964c7791524bf84074d7bc087b7392957520e24cde77e6580a84 · Zeichen 1715–2596 im Abschnitt